Fenbendazole – Summary Report (3): metabolism and target organ (1997)

Government Record · Committee for Veterinary Medicinal Products (CVMP), EMEA · June 1997

Committee for Veterinary Medicinal Products (CVMP), 1997-06: The EU monograph states that fenbendazole is metabolised in mammals to a series of other benzimidazoles including oxfendazole, that elimination is predominantly faecal, and that the liver is the main target tissue in all species tested.

Fenbendazole is a benzimidazole anthelmintic compound that is metabolised in mammals to a series of other benzimidazoles including oxfendazole

1

Committee for Veterinary Medicinal Products (CVMP), 1997-06: The EU monograph states that fenbendazole is metabolised in mammals to a series of other benzimidazoles including oxfendazole, that elimination is predominantly faecal, and that the liver is the main target tissue in all species tested. F2. The book says fenbendazole metabolism is 'less dependent on hepatic pathways'; this document shows hepatic conversion to oxfendazole and the liver as the target organ, with faecal excretion of metabolites. Both halves recorded: metabolism is hepatic, elimination is largely faecal. Also gives plasma half-lives 6 h (rat), 13 h (rabbit), 15 h (dog), 2-3 days (sheep), and Cmax about 8 h in rats/rabbits and 24 h in dogs – i.e. no human pharmacokinetic data at all. Also filed as FBA-37, FBA-58 (claims C8, F1, F2). Study type: regulatory record.